MetaCap

Akari Therapeutics (AKTX) vs Shuttle Pharmaceuticals (SHPH)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Akari Therapeutics (AKTX) has outperformed Shuttle Pharmaceuticals (SHPH) over the past year, losing 60.1% versus a loss of 78.2%. Akari Therapeutics is the larger company by market cap ($16.7 million vs $16.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AKTX-60.11%SHPH-78.19%
+63%-13%-90%
Nov 21, 20251 yearNov 20, 2026
AKTX-99.21%SHPH-99.99%
+173%+30%-113%
Aug 29, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AKTX versus SHPH key metrics
MetricAKTXSHPH
Share price$7.18$3.49
Market cap$16.70M$16.63M
1-day change+7.00%-10.51%
YTD return-37.89%-80.61%
1-year return-60.11%-78.19%
5-year return-99.47%—
EPS (TTM)$0.00$-16.87
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-17.30M$-11.72M
52-week high$29.32$44.40
52-week low$3.02$2.58
Distance from 52-week high-75.51%-92.14%
Analyst consensusnone—
Avg. price target upside+255.15%—
Average volume58.54K41.80K
Shares outstanding2.33M4.76M
Employees52
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AKTX has outperformed SHPH by 18.1 percentage points over the past year.

About Akari Therapeutics

AKTX stock →

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

About Shuttle Pharmaceuticals

SHPH stock →

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

AKTX vs SHPH FAQ

Which is bigger, Akari Therapeutics or Shuttle Pharmaceuticals?

Akari Therapeutics (AKTX) is larger, with a market capitalization of $16.70M compared with $16.63M for Shuttle Pharmaceuticals (SHPH).

Which stock has performed better over the past year, AKTX or SHPH?

AKTX returned -60.11% over the past 12 months, compared with -78.19% for SHPH (price return, excluding dividends). Past performance does not predict future results.

Are Akari Therapeutics and Shuttle Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons